Show simple item record

dc.contributor.authorBarker, Claire L
dc.contributor.authorRoutledge, Jacqueline A
dc.contributor.authorFarnell, Damian J J
dc.contributor.authorSwindell, Ric
dc.contributor.authorDavidson, Susan E
dc.date.accessioned2009-06-02T14:25:50Z
dc.date.available2009-06-02T14:25:50Z
dc.date.issued2009-05-19
dc.identifier.citationThe impact of radiotherapy late effects on quality of life in gynaecological cancer patients. 2009, 100 (10):1558-65 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid19384297
dc.identifier.doi10.1038/sj.bjc.6605050
dc.identifier.urihttp://hdl.handle.net/10541/69601
dc.description.abstractThe aims of this study were to assess changes in quality of life (QoL) scores in relation to radical radiotherapy for gynaecological cancer (before and after treatment up to 3 years), and to identify the effect that late treatment effects have on QoL. This was a prospective study involving 225 gynaecological cancer patients. A QoL instrument (European Organisation for the Research and Treatment of Cancer QLQ-C30) and late treatment effect questionnaire (Late Effects Normal Tissues - Subjective Objective Management Analysis) were completed before and after treatment (immediately after radiotherapy, 6 weeks, 12, 24 and 36 months after treatment). Most patients had acute physical symptoms and impaired functioning immediately after treatment. Levels of fatigue and diarrhoea only returned to those at pre-treatment assessment after 6 weeks. Patients with high treatment toxicity scores had lower global QoL scores. In conclusion, treatment with radiotherapy for gynaecological cancer has a negative effect on QoL, most apparent immediately after treatment. Certain late treatment effects have a negative effect on QoL for at least 2 years after radiotherapy. These treatment effects are centred on symptoms relating to the rectum and bowel, for example, diarrhoea, tenesmus and urgency. Future research will identify specific symptoms resulting from late treatment toxicity that have the greatest effect on QoL; therefore allowing effective management plans to be developed to reduce these symptoms and improve QoL in gynaecological cancer patients.
dc.language.isoenen
dc.subjectRadiotherapyen
dc.subjectLate Toxicityen
dc.subjectQuality of Lifeen
dc.subjectGynaecological Canceren
dc.subjectLongitudinal Studyen
dc.titleThe impact of radiotherapy late effects on quality of life in gynaecological cancer patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK. claire.barker@doctors.org.uken
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe aims of this study were to assess changes in quality of life (QoL) scores in relation to radical radiotherapy for gynaecological cancer (before and after treatment up to 3 years), and to identify the effect that late treatment effects have on QoL. This was a prospective study involving 225 gynaecological cancer patients. A QoL instrument (European Organisation for the Research and Treatment of Cancer QLQ-C30) and late treatment effect questionnaire (Late Effects Normal Tissues - Subjective Objective Management Analysis) were completed before and after treatment (immediately after radiotherapy, 6 weeks, 12, 24 and 36 months after treatment). Most patients had acute physical symptoms and impaired functioning immediately after treatment. Levels of fatigue and diarrhoea only returned to those at pre-treatment assessment after 6 weeks. Patients with high treatment toxicity scores had lower global QoL scores. In conclusion, treatment with radiotherapy for gynaecological cancer has a negative effect on QoL, most apparent immediately after treatment. Certain late treatment effects have a negative effect on QoL for at least 2 years after radiotherapy. These treatment effects are centred on symptoms relating to the rectum and bowel, for example, diarrhoea, tenesmus and urgency. Future research will identify specific symptoms resulting from late treatment toxicity that have the greatest effect on QoL; therefore allowing effective management plans to be developed to reduce these symptoms and improve QoL in gynaecological cancer patients.


This item appears in the following Collection(s)

Show simple item record